Atomic-Level Matching Metal-Ion Organic Hybrid Interface to Enhance Energy Storage of Polymer-Based Composite Dielectrics.

In this work, a distinctive "metal-ion organic hybrid interface" (MOHI) between polyimide (PI) and calcium niobate (CNO) nanosheets is designed. The metal ions in the MOHI can achieve atomic-level matching not only with the inorganic CNO, but also with the PI chains, forming uniform and strong chemical bonds. These results are demonstrated by experiment and theory calculations.

Enhanced Lithium Storage Performance of α-MoO/CNTs Composite Cathode.

Orthorhombic molybdenum oxide (α-MoO), as a one-layered pseudocapacitive material, has attracted widespread attention due to its high theoretical lithium storage specific capacity (279 mAh/g) for lithium-ion batteries' cathode. Nevertheless, low conductivity, slack reaction kinetics, and large volume change during Li ions intercalation and deintercalation seriously limit the practical application of α-MoO. Herein, we added a small number of CNTs (1.

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.

Background: NKTR-255 is a novel polyethylene glycol-conjugate of recombinant human interleukin-15 (rhIL-15), which was designed to retain all known receptor binding interactions of the IL-15 molecule. We explored the biologic and pharmacologic differences between endogenous IL-15 receptor α (IL-15Rα)-dependent (NKTR-255 and rhIL-15) and IL-15Rα-independent (precomplexed rhIL-15/IL-15Rα) cytokines.

Methods: In vitro pharmacological properties of rhIL-15, NKTR-255 and precomplex cytokines (rhIL-15/IL-15Rα and rhIL-15 N72D/IL-15Rα Fc) were investigated in receptor binding, signaling and cell function.

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Purpose: Aldesleukin, recombinant human IL2, is an effective immunotherapy for metastatic melanoma and renal cancer, with durable responses in approximately 10% of patients; however, severe side effects limit maximal dosing and thus the number of patients able to receive treatment and potential cure. NKTR-214 is a prodrug of conjugated IL2, retaining the same amino acid sequence as aldesleukin. The IL2 core is conjugated to 6 releasable polyethylene glycol (PEG) chains.